Stephanie Barbanell is an associate in the firm’s Business Law department and a member of its Technology group, and Public M&A/Corporate governance practice.
Professional Experience
Her recent M&A experience includes representing:
- Orchard Therapeutics in its sale to Kyowa Kirin
- EQRx in its sale to Revolution Medicines in an all-stock transaction intended to add more than $1 billion in net cash to Revolution Medicines’ balance sheet
- Magenta Therapeutics in its reverse merger with Dianthus Therapeutics
- Intapp in its acquisition of Paragon Data Labs
- TCR2 in its cross-border all-stock combination with Adaptimmune
- Frazier Lifesciences Acquisition Corporation in its business combination with NewAmsterdam Pharma
- Forma Therapeutics in its $1.1 billion sale to Novo Nordisk
- KVH Industries in its $55 million sale of its inertial navigation business to EMCORE
- SYLVAIN in its sale to kyu
- BioDelivery Sciences International in its $605 million sale to Collegium Pharmaceutical
- Retail Properties of America in its $7.5 billion sale to Kite Realty Group Trust
- Leaf Group in its $323 million sale to Graham Holdings Company
- Special Committee of NantKwest in NantKwest’s merger with ImmunityBio
- MyoKardia in connection with its $13.1 billion sale to Bristol-Myers Squibb Company
- Xeris in in its cross-border acquisition of Strongbridge Biopharma for stock and CVRs valued at $267 million
Credentials
Education
JD2020
Georgetown University Law Center
BSBAMarketing2017
University of Florida
Admissions
Bars
- New York
Recognition & Awards
While attending Georgetown Law, Stephanie was on the Environmental Law Journal.